Three-Year Efficacy and Safety of Revi Implantable Tibial Neuromodulation from the Pivotal OASIS Study
Authors:
- Cindy L. AmundsenCACindy L. Amundsen
- Suzette E. SutherlandSSSuzette E. Sutherland
- John P. F. A. HeesakkersJohn P. F. A. Heesakkers
- Philip Toozs-HobsonPTPhilip Toozs-Hobson
- Frank MartensFMFrank Martens
- Rebecca J. McCreryRMRebecca J. McCrery
- Peter R. RodinePRPeter R. Rodine
- Roger R. DmochowskiRDRoger R. Dmochowski
Open Access
- 1 August 2026
- journal article
- Published by Wolters Kluwer Health in Journal of Urology
- Vol. 216 (2) , 219-229
Abstract
Revi® is a novel implantable tibial neuromodulation (iTNM) system powered by an external, battery-operated wearable that facilitates individually tailored stimulation to provide treatment for urgency urinary incontinence (UUI). The Revi System (manufactured by BlueWind Medical) is the first FDA-cleared implantable neuromodulation device that can be used in traditionally non-refractory patients. Three-year follow-up results from the pivotal FDA-approval trial, the OASIS Study, are presented. The Revi System was implanted in 151 women. The primary efficacy and safety endpoints were assessed at 6 and 12 months, respectively; thereafter, participants were consented to extend follow-up to 3 years for assessments of long-term treatment durability and safety. Ninety-three percent (140/151) completed the 12-month study and 85% (119/140) met screening criteria and consented to the 36-month extension study. Ninety participants (76%, (90/119) completed the 36-month assessment and 79% (71/90) were therapy responders (≥ 50% reduction in UUI episodes, demonstrated on a 3-day voiding diary). Sustained therapeutic responses were reported, with durable effectiveness between 6 and 36 months (response rates of 78% and 79%, respectively).Notably, 95% (83/87) reported therapeutic satisfaction and 82% (74/90) reported feeling "much better" or "very much better" based on the Patient Global Impression of Improvement (PGI-I) scale. No device- or procedure- related serious adverse events were reported through 36 months. In women with UUI, Revi - an iTNM system powered by a patient-controlled, external wearable ankle device - showed meaningful and durable efficacy, high patient satisfaction, and an excellent safety profile through 3 years.Keywords
This publication has 13 references indexed in Scilit:
- Two-year Pivotal Study Analysis of the Safety and Efficacy of Implantable Tibial Nerve Stimulation With eCoin® for Urgency Urinary IncontinenceUrology, 2024
- The AUA/SUFU Guideline on the Diagnosis and Treatment of Idiopathic Overactive BladderJournal of Urology, 2024
- Tibial Nerve Stimulation for Urge Urinary Incontinence and Overactive Bladder: Narrative Review of Randomized Controlled Trials and Applicability to Implantable DevicesAdvances in Therapy, 2024
- A prospective study to assess the effectiveness and safety of the BlueWind System in the treatment of patients diagnosed with urgency urinary incontinenceNeurourology and Urodynamics, 2024
- Five-year Results from the Prospective, Multicenter, Observational SOUNDS Study of Patients with Overactive Bladder Treated with the InterStim System for Sacral NeuromodulationEuropean Urology Focus, 2023
- Comparing the Efficacy of OnabotulinumtoxinA, Sacral Neuromodulation, and Peripheral Tibial Nerve Stimulation as Third Line Treatment for the Management of Overactive Bladder Symptoms in Adults: Systematic Review and Network Meta-AnalysisToxins, 2020
- Five-Year Followup Results of a Prospective, Multicenter Study of Patients with Overactive Bladder Treated with Sacral NeuromodulationJournal of Urology, 2018
- Clinical characteristics, beliefs, and coping strategies among older patients with overactive bladderNeurourology and Urodynamics, 2016
- Global Prevalence and Economic Burden of Urgency Urinary Incontinence: A Systematic ReviewEuropean Urology, 2014
- Psychometric validation of an overactive bladder symptom and health-related quality of life questionnaire: The OAB-qQuality of Life Research, 2002